CJC-1295 sits in the growth hormone-releasing hormone (GHRH) analog family, working upstream by prompting the pituitary's own somatotrophs to release growth hormone rather than supplying the hormone directly. The honest bottom line up front: among the agents it is compared against, only tesamorelin and recombinant human growth hormone (somatropin) hold FDA approval, while CJC-1295 holds none, so any comparison has to keep approval status accurate rather than implying these agents are interchangeable. Where CJC-1295 most distinguishes itself within its own family is duration, with the DAC-bound form stretching the half-life to roughly six to eight days.
| Comparison axis | CJC-1295 (with DAC) | Same-family GHRH analogs | Ghrelin-receptor agonists | Recombinant GH (somatropin) |
|---|---|---|---|---|
| Mechanism | Stimulates pituitary via GHRH receptor | Stimulates pituitary via GHRH receptor | Mimics ghrelin at GHS-R1a | Supplies GH directly, bypasses pituitary |
| Duration of action | Half-life ~6 to 8 days | Minutes (sermorelin) to once-daily (tesamorelin) | Sharp, short GH spike | Direct, typically daily dosing |
| FDA approval | None | Tesamorelin approved (HIV lipodystrophy) | None | Approved for defined indications |
CJC-1295 is distinguished from same-family GHRH analogs primarily by its roughly six-to-eight-day DAC half-life, from the ghrelin-agonist family by its receptor target, and from direct recombinant growth hormone by whether the pituitary is stimulated or bypassed, while holding no FDA approval that tesamorelin and somatropin do.
Growth hormone secretagogues sort into a small number of mechanistic classes defined by which receptor they engage, and CJC-1295's place among them is the single most important fact for situating it against the alternatives. It falls cleanly into the GHRH-analog class, defined within that group by four amino-acid substitutions for protease resistance and, in the with-DAC version, by an albumin-binding group that greatly extends its action.
CJC-1295 falls cleanly into the GHRH-analog class as a long-acting member, set apart from the ghrelin-receptor agonists and the orally active non-peptide secretagogues by both its receptor target and its DAC-extended duration.
All three agents are built on the GHRH(1-29) sequence that carries the parent hormone's full biological activity, so the divergence among them is not the backbone but how each is stabilized and therefore how long it acts. The published record places the practical fault line at duration: sermorelin clears in minutes and produces a brief physiologic pulse, while CJC-1295 with DAC produces a prolonged elevation often described as a bleed or plateau. Among the three, tesamorelin is the only FDA-approved member and the only one backed by a large clinical trial record.
| Agent | Structural modification | Half-life / dosing | Approval status |
|---|---|---|---|
| Sermorelin | Native GHRH(1-29) | Order of minutes; frequent dosing | Not FDA-approved as this analog |
| Tesamorelin | Added trans-3-hexenoyl group | Once-daily subcutaneous | FDA-approved (HIV-associated lipodystrophy) |
| CJC-1295 (with DAC) | Four substitutions plus maleimide-albumin DAC | Roughly six to eight days | Not FDA-approved |
Sermorelin, tesamorelin, and CJC-1295 share the GHRH(1-29) backbone but diverge by stabilization, with the DAC-bound form of CJC-1295 reaching a roughly six-to-eight-day half-life that departs from natural pulsatility and lacks the trial record backing FDA-approved tesamorelin.
The mechanistic split comes down to two different receptors and two different physiological levers. CJC-1295 binds the GHRH receptor and amplifies the body's own releasing signal, essentially turning up the volume on the stimulatory limb, while ipamorelin, GHRP-6, and hexarelin bind the ghrelin receptor (GHS-R1a) and both trigger release directly and blunt the inhibitory somatostatin brake. The published record notes the practical consequence for any reader weighing the two: because the families pull different levers, they are widely combined rather than measured strictly head-to-head.
A GHRH analog such as CJC-1295 and a ghrelin-receptor agonist such as ipamorelin engage two different receptors and pull two opposing levers of growth hormone control, which is why the literature frames them as complementary and frequently combined rather than as direct substitutes.
The with-DAC versus without-DAC distinction is the defining variable that separates CJC-1295 from nearly every other secretagogue on the duration axis. DAC stands for drug affinity complex, a maleimidopropionic acid group that bonds covalently to a free cysteine thiol on serum albumin, tethering the peptide to a large carrier protein so the kidneys cannot quickly filter it out. The literature flags a real source of confusion for any reader: the without-DAC form is frequently sold as modified GRF(1-29) or mislabeled simply as CJC-1295, even though the two forms behave completely differently in duration.
The DAC group extends CJC-1295's half-life from minutes to roughly six to eight days by covalently binding serum albumin, which separates the with-DAC form's sustained GH and IGF-1 elevation from the short, pulsatile action of without-DAC modified GRF(1-29) and other short-acting secretagogues.
Regulatory status is one of the sharpest dividing lines among the secretagogues, and the comparison has to be stated precisely so it never reads as if these agents are interchangeable in the eyes of the law. CJC-1295 is not approved by the FDA for any human indication and has never completed the trials required for marketing authorization, while within its own family tesamorelin is the notable exception that cleared the regulatory bar CJC-1295 has not. The compounding landscape has been unsettled rather than settled in CJC-1295's favor.
CJC-1295 is not FDA-approved and is not an established compoundable bulk substance, in contrast to tesamorelin and recombinant growth hormone, which hold FDA approval, and it appears on the World Anti-Doping Agency prohibited list under the GHRH and growth hormone secretagogue categories.
Comparing safety across the secretagogues is constrained from the outset by how little controlled human data exists for most of them, so the picture is largely reported adverse events plus mechanism-based theoretical risk rather than established trial outcomes. CJC-1295 with DAC carries a specific historical note that sets it apart from agents that only lack data: its clinical development was halted after a participant death was reported in an early trial, an event variously attributed to unrelated causes but one that ended formal development. None of these comparisons rest on long-term controlled human trials, so they read as informed caution rather than a settled risk ranking.
CJC-1295 with DAC is distinguished from competing secretagogues by a halted early clinical program following a reported participant death, while the category-wide theoretical risk of sustained growth hormone and IGF-1 elevation weighs most heavily on long-acting agents and rests on no long-term controlled human trials.
GHRH analogs and ghrelin-receptor agonists are so often combined because they act on the two opposing controls of growth hormone release at the same time, and the body's regulation responds more than additively when both are engaged. A GHRH analog like CJC-1295 raises the stimulatory releasing signal, while a ghrelin agonist like ipamorelin adds an independent release stimulus and suppresses the somatostatin brake, so pushing the accelerator while easing off the brake yields a synergistic rather than simply summed pulse. This combination framing is what most distinguishes CJC-1295's practical role from a head-to-head comparison, positioning it as one half of a two-part stack rather than a standalone competitor.
GHRH analogs and ghrelin-receptor agonists are combined because engaging both the stimulatory signal and the somatostatin brake yields a synergistic rather than additive growth hormone response, which positions CJC-1295 as the durable releasing half of a two-part stack rather than a standalone agent measured head-to-head.
The comparison between CJC-1295 and recombinant human growth hormone is a contrast between stimulating a gland and replacing its product. Somatropin is the growth hormone molecule itself injected directly, so it raises circulating GH and downstream IGF-1 regardless of what the pituitary is doing, whereas CJC-1295 prompts the pituitary's own somatotrophs and is therefore limited by the gland's capacity. The argument that secretagogues better preserve physiologic pulsatility is mechanistic reasoning rather than a proven clinical advantage, and the regulatory contrast is decisive: recombinant growth hormone is an FDA-approved prescription drug, while CJC-1295 holds no approval.
| Comparison axis | CJC-1295 | Recombinant GH (somatropin) |
|---|---|---|
| Action | Stimulates pituitary somatotrophs | Supplies GH directly, bypasses the gland |
| Ceiling | Limited by pituitary capacity | Not limited by gland responsiveness |
| Feedback | Works within negative feedback | Suppresses natural output via feedback |
| Regulatory | No FDA approval, research-chemical territory | FDA-approved prescription for defined indications |
| Cost / supply | Shaped by unapproved, gray-market supply | Expensive, established prescription supply chains |
CJC-1295 stimulates the pituitary and is capped by the gland's capacity while working within negative feedback, whereas FDA-approved recombinant growth hormone supplies the hormone directly and suppresses natural output, making the mechanistic and regulatory differences, not cost, the load-bearing distinction.
Educational use only. This article describes what the published scientific and clinical literature reports about CJC-1295. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
